Elderly Patients and COVID-19 Infection: a Cohort of Fifty Patients Over Ninety Years of Age

Covid19 Clinical Trial

Official title:

Elderly Patients and COVID-19 Infection: a Cohort of Fifty Patients Over Ninety Years of Age

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04499300
• Other study ID #: CHUB-COVID-19-90+
• Status: Completed
• Start date: June 9, 2020
• Est. completion date: November 23, 2020

Study information

• Verified date: March 2022
• Source: Brugmann University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

SARS-CoV2 or CoVid19 disease is a newly described pathology linked to a subtype of the coronavirus family identified in China in December 2019. This pathology can present multiple clinical facets, ranging from asymptomatic forms to more commonly critical pulmonary forms called "Acute Respiratory Distress Syndrome". The elderly population is more at risk for this infection due to the senescence of the immune system, co-morbidities and poly medications. They also often present a greater state of fragility.

This study aims to report the epidemiology of the first 50 patients over 90 years of age hospitalized within the CHU Brugmann hospital.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: November 23, 2020
• Est. primary completion date: November 23, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 90 Years and older

Eligibility

Inclusion Criteria:

• Be over 90 years of age on the date of admission to CHU Brugmann Hospital

• Have a SARS Cov2 infection proven by antigen or RT-PCR on smear and / or typical imaging regardless of the clinical manifestation

• Have been hospitalized at CHU Brugmann between 03/01/2020 and 05/10/2020

Exclusion Criteria:

None

Related Conditions & MeSH terms

• COVID-19
• Covid19

Intervention

Other:
• Data collection from medical files
Data collection from medical files

Locations

Country	Name	City	State
Belgium	CHU Brugmann	Brussels

Sponsors (1)

Lead Sponsor	Collaborator
Murielle Surquin

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Demographic data	Age, sex, ethnicity	5 minutes
Primary	Comorbidities	Smoking, Obesity, Diabetes, Arterial hypertension, Coronary pathology, Cerebrovascular disease, chronic renal failure, chronic obstructive pulmonary disease, Neoplasia, Autoimmune disease, Chronic liver disease	5 minutes
Primary	Cumulative Illness Rating Scale-Geriatric (CIRS-G)	CIRS-G quantifies burden of disease in elderly patients (comorbidity scale). Higher scores indicate higher severity (maximum score = 56 points).	5 minutes
Primary	Treatments	Under Chronic corticosteroid therapy or Immunosuppressive therapy	5 minutes
Primary	Signs and symptoms	Presence and date of first apparition: Fever, Cough, Dyspnea, Chest pain, Nausea or vomiting, Diarrhea, Fatigue, Anosmia, ageusia, inappetence, Confusion, Fall, Fracture	5 minutes
Primary	Fever	Vital signs at hospital admission: Fever	5 minutes
Primary	Hypoxemia	Vital signs at hospital admission: Hypoxemia	5 minutes
Primary	Tachycardia	Vital signs at hospital admission:Tachycardia	5 minutes
Primary	Hypotension	Vital signs at hospital admission: Hypotension	5 minutes
Primary	Gasometry	Vital signs at hospital admission: Gasometry	5 minutes
Primary	Infectious data	Contact with confirmed covid person before admission, lives in a retirement home with other cases, Initial bacterial or viral co-infection, Bacterial or viral co-infection during the hospital stay	5 minutes
Primary	Blood count	Blood count at hospital admission or first recorded	5 minutes
Primary	Ionogram	Ionogram at hospital admission or first recorded	5 minutes
Primary	Liver function	Liver function at hospital admission or first recorded	5 minutes
Primary	Coagulation	Coagulation at hospital admission or first recorded	5 minutes
Primary	Renal function	Renal function at hospital admission or first recorded	5 minutes
Primary	Albumin	Albumin at hospital admission or first recorded	5 minutes
Primary	CRP	CRP at hospital admission or first recorded	5 minutes
Primary	Fibrinogen	Fibrinogen at hospital admission or first recorded	5 minutes
Primary	D-dimers at hospital admission or first recorded	D-dimers	5 minutes
Primary	NTproBNP	NTproBNP at hospital admission or first recorded	5 minutes
Primary	CK	CK at hospital admission or first recorded	5 minutes
Primary	Troponin	Troponin at hospital admission or first recorded	5 minutes
Primary	Ferritin	Ferritin at hospital admission or first recorded	5 minutes
Primary	Procalcitonin	Procalcitonin at hospital admission or first recorded	5 minutes
Primary	Biology - highest rate	Highest rate of CRP, D-Dimers, Urea, Creatinin, Fibrinogen, CK, Troponins	5 minutes
Primary	Biology - lowest rate	Lowest rate of hemoglobin, platelets, leucocytes, lymphocytes, albumin, Na+, K+	5 minutes
Primary	Percentage of pulmonary involvement on chest CT scan	Percentage of pulmonary involvement on chest CT scan	5 minutes
Primary	Number of pulmonary lobes affected	Number of pulmonary lobes affected	5 minutes
Primary	Type of lesions	Type of lesions as reflected on the CT scan images: 'Ground glass' or 'Crazy paving'	5 minutes
Primary	Need for oxygenotherapy	Need for oxygenotherapy (yes/no)	5 minutes
Primary	Means of ventilation	Means of ventilation	5 minutes
Primary	Treatment received	Hydroxychloroquine or Azithromycin	5 minutes
Primary	Length of ICU Stay	Length of ICU Stay	5 minutes
Primary	Status at hospital exit	One of the following choices: death, went back home, went back to a retirement home, was placed in a revalidation unit.	5 minutes
Primary	Mortality	28-day mortality after PCR / CT scan / diagnosis	5 minutes